First Patients Treated in India Using CyberKnife Radiosurgery
SUNNYVALE, Calif., Apr. 3 /PRNewswire-AsiaNet/ --
Newly Installed System at Apollo Hospital Treats Six and Preps Eight Patients in First Week
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that
the first patients in India have been treated using CyberKnife radiosurgery. The CyberKnife System, which is
located at the Apollo Specialty Cancer Hospital in Chennai, India, treated six patients in its first week of
operation, with eight more patients in the treatment planning process being readied for treatment.
"Our new CyberKnife System allows us to deliver highly precise radiosurgical treatments to patients with
tumors throughout the body," said Prathap C. Reddy, M.D., executive chairman, Apollo Hospitals Group. "We
are very glad to have begun treating patients and look forward to witnessing the benefits that the System
offers, including real-time tracking of tumors that move with respiration."
The CyberKnife treatment team at Apollo Hospital consists of a trained team of highly experienced radiation
oncologists, radiation therapists and a neurosurgeon. The team plans to focus on CyberKnife radiosurgery for
lung, liver and prostate treatment as well as head, neck and spine treatments. Lung cancer is currently one of
the leading cancer incidences and causes of death amongst men in India. (National Cancer Registry, ICMR-
New Delhi)
"Since India is the second most populous nation in the world, we are excited that CyberKnife radiosurgery is
now an option for its population and that the first patients have received treatment," said Eric P. Lindquist,
senior vice president and chief marketing officer at Accuray. "We believe this is just the first step in the
opening of a large market for the CyberKnife System, as illustrated by the momentum within this System's first
week of use."
Advanced Medical Systems (headquartered in Singapore), the company responsible for placing the
CyberKnife at Apollo Hospital, will assist in marketing and providing end user support for the new CyberKnife
System through its Accuray trained team of engineers and applications specialists based in India.
About Apollo Hospitals
It was in 1983 that Dr. Prathap Reddy made a pioneering endeavor by launching India's first corporate
hospital - Apollo Hospital in Chennai. An integrated healthcare company, the group has around 10,000 beds
across 45 hospitals, more than 750 pharmacies and 100 diagnostic clinics, medical business process
outsourcing services, health insurance services, and clinical research divisions with a focus on epidemiological
studies, stem cell research and genetic research. To develop talent for the burgeoning need of superior
healthcare delivery, the group has 10 nursing and hospital management colleges. Harnessing technology to
enhance access across India and share the repository of knowledge, there are more than 100 telemedicine
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to
treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and
patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-
dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates
the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of
radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those
diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which
extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate,
liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients
worldwide and currently more than 155 systems have been installed in leading hospitals in the Americas,
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including
uncertainties associated with the medical device industry. Except for the historical information contained
herein, the matters set forth in this press release, including statements relating to commercialization of
products, regulatory review and approval and clinical studies are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements speak only as of the date the statements are made and are based on information available
at the time those statements are made and/or management's good faith belief as of that time with respect to
future events. You should not put undue reliance on any forward-looking statements. Important factors that
could cause actual performance and results to differ materially from the forward-looking statements we make
include: market acceptance of products; competing products, the combination of our products with
complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our
report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on February 5, 2009 and our
other filings with the Securities and Exchange Commission. The Company's actual results of operations may
differ significantly from those contemplated by such forward-looking statements as a result of these and other
factors. We assume no obligation to update forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors affecting forward-looking information, except to
the extent required by applicable securities laws.
SOURCE: Accuray Incorporated
CONTACT: Stephanie Tomei,
Senior Manager,
Public Relations of Accuray Incorporated,
+1-408-789-4234,
stomei@accuray.com;
or Brianne Donahue of Schwartz Communications,
+1-415-817-2545,
bdonahue@schwartz-pr.com,
for Accuray Incorporated
(ARAY)
__________________________________________________________________________________________